UCARTCS-1A is under clinical development by Cellectis and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect UCARTCS-1A’s likelihood of approval (LoA) and phase transition for Refractory Multiple Myeloma took place on 01 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 01 Jun 2021 decreased UCARTCS-1A’s LoA and PTSR for Relapsed Multiple Myeloma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their UCARTCS-1A Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

UCARTCS-1A overview

UCARTCS-1 is under development for the treatment of relapsed and refractory multiple myeloma (MM). The drug candidate is an allogeneic gene-edited T-cell product candidate. The therapeutic candidate is administered as infusion. It acts by targeting CS1 antigen. It is developed based on CAR-T platform technology. It was also under development for B-Cell chronic lymphocytic leukemia (B-CLL).

Cellectis overview

Cellectis, operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company pioneer’s gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It develops treatment based on allogeneic T-cell for the treatment of cancer. Cellectis therapeutic pipeline products include products for hematopoietic tumors includes UCART19, UCARTS1, UCART123, UCART22, UCART-BCMA and UCART38; and products for solid tumors including UCART5T4, UCART-EgfrVIII, s-3, s-4, s-5, s-6, and s-7. The company carries out research and development in the field of oncology and gene editing. It operates in New York and Paris. Cellectis is headquartered in Paris, France.

Quick View UCARTCS-1A LOA Data

Report Segments
  • Innovator
Drug Name
  • UCARTCS-1A
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.